申请人:Jubault Philippe
公开号:US20120190648A1
公开(公告)日:2012-07-26
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a mixture in all proportions of stereoisomers thereof, in particular a mixture of enantiomers, such as a racemic mixture, wherein R represents a (C
1
-C
6
)alkyl or (C
1
-C
6
)alkenyl group, optionally substituted by one or more groups chosen among an halogen atom, OR
a
, SR
b
, NR
c
R
d
, PO(OR
e
)(OR
f
), CO
2
R
g
, SO
2
R
h
SO
3
R
1
, P0(0H)(CH(0H)R
k
), CN, N
3
and NH—C(═NH)NH2, with R
a
, R
b
, R
c
and R
d
, representing, independently of each other, an hydrogen atom, a (C
1
-C
6
)alkyl group or a —CO—(C
1
-C
6
)alkyl group, R
e
, R
f
, R
g
, R
h
and R1 representing, independently of each other, an hydrogen atom or a (C
1
-C
6
)alkyl group, and R
k
representing an aryl or heteroaryl group, said group being optionally substituted by one or more groups selected from an halogen atom and NO
2
, as well as to the use thereof and to a process for preparing such a compound, to a pharmaceutical composition containing it and to synthesis intermediates.
本发明涉及一种式(I)的化合物或其药学上可接受的盐、立体异构体或其立体异构体的任意比例混合物,特别是对映体混合物,例如混合的外消旋体,其中R代表(C1-C6)烷基或(C1-C6)烯基基团,可选地被一个或多个从卤素原子、ORa、SRb、NRcRd、PO(ORe)(ORf)、CO2Rg、SO2RhSO3R1、P0(0H)(CH(0H)Rk)、CN、N3和NH—C(═NH)NH2中选择的基团取代,其中Ra、Rb、Rc和Rd分别独立地表示氢原子、(C1-C6)烷基或—CO—(C1-C6)烷基,Re、Rf、Rg、Rh和R1分别独立地表示氢原子或(C1-C6)烷基,而Rk表示芳基或杂环基团,该基团可选地被一个或多个从卤素原子和
NO2中选择的基团取代,以及其使用和制备该化合物的方法,包括含有该化合物的制药组合物和合成中间体。